Exozymes Inc. CEO Michael Heltzen purchased 855 ordinary shares on Aug. 25 and 26, totaling $6,405 at prices ranging from $7.35 to $7.60 per share.
The transactions follow an earlier purchase on Aug. 19, when Heltzen acquired 8,841 shares at $6.40 each, worth $56,582. His direct ownership now stands at 14,708 shares.
Exozymes reported a net loss of $2.88 million in the second quarter of 2026, with a trailing twelve-month loss of $1.20 per share. The company’s cash position stood at $5.65 million at quarter-end, providing liquidity projected to cover operations through the end of 2026. The stock was trading at $6.79 on the filing date, up $0.19, or 2.88%.
The company, which has not yet generated revenue, is focused on commercializing its core product, NCT, described as offering significant productivity improvements. Resources are directed toward product development, pipeline advancement, and market entry. The regulatory filing was signed on Sept. 2, 2026.
